Robert Alexander, MD
Dr. Alexander is currently the Chief Scientific Officer of the Alzheimer’s Prevention Initiative
at the Banner Alzheimer’s Institute in Phoenix, Arizona. Previously, he was a VP in the
neuroscience therapeutic area unit at Takeda. Prior to that, Dr. Alexander worked for Pfizer as
VP and head of clinical for the neuroscience and pain research unit, and AstraZeneca where he
was VP of clinical for CNS and the pain innovative medicines unit (iMed). His other prior
positions include VP and head of discovery medicine and CMO of the Neurosciences Centre for
Excellence in Drug Discovery at GlaxoSmithKline and senior director in the clinical neuroscience
and clinical pharmacology at Merck Research Labs.
Dr. Alexander is an expert in psychopharmacology and has extensive experience in both early- and
late-stage drug development and medical governance. He has conducted or supervised clinical
studies in a broad range of neurologic and psychiatric indications, including Alzheimer's
disease (AD), Parkinson’s disease (PD), Huntington’s disease, pain, multiple sclerosis,
Friedreich’s Ataxia, Tourette’s syndrome, epilepsy, sleep disorders, tinnitus, major depression,
bipolar disorder, anxiety disorders, schizophrenia, and sexual dysfunction.